Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex

Beckie Michael, Steven Fishbane, Daniel W. Coyne, Rajiv Agarwal, David G. Warnock

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Intravenous iron is necessary for optimal management of anemia in patients receiving hemodialysis and is utilized in the majority of these patients in the US. The availability of nondextran formulations of intravenous iron has significantly improved the safety of its use. The nondextran iron formulation sodium ferric gluconate complex (SFGC) has been extensively studied in the hemodialysis population, with two large phase IV trials documenting its safety. SFGC is efficacious and, at recommended doses, is associated with a low incidence of adverse events. There have been few comparative studies of the nondextran intravenous iron preparations; however, they are known to have different pharmacokinetic characteristics. There is also evidence to indicate that these compounds differ in terms of their cytotoxic and proinflammatory properties, and their propensity to induce oxidative stress. This paper reviews the current literature on the safety of SFGC and examines the emerging safety issues surrounding the use of intravenous iron.

Original languageEnglish (US)
Pages (from-to)92-100
Number of pages9
JournalNature Clinical Practice Nephrology
Volume2
Issue number2
DOIs
StatePublished - Feb 1 2006

Fingerprint

Iron
Safety
Pharmaceutical Preparations
Renal Dialysis
Anemia
Oxidative Stress
Pharmacokinetics
ferric gluconate
gluconic acid
Incidence
Population

Keywords

  • Anemia
  • End-stage renal disease
  • Intravenous iron
  • Iron deficiency
  • Sodium ferric gluconate complex

ASJC Scopus subject areas

  • Nephrology

Cite this

Drug insight : Safety of intravenous iron supplementation with sodium ferric gluconate complex. / Michael, Beckie; Fishbane, Steven; Coyne, Daniel W.; Agarwal, Rajiv; Warnock, David G.

In: Nature Clinical Practice Nephrology, Vol. 2, No. 2, 01.02.2006, p. 92-100.

Research output: Contribution to journalReview article

Michael, Beckie ; Fishbane, Steven ; Coyne, Daniel W. ; Agarwal, Rajiv ; Warnock, David G. / Drug insight : Safety of intravenous iron supplementation with sodium ferric gluconate complex. In: Nature Clinical Practice Nephrology. 2006 ; Vol. 2, No. 2. pp. 92-100.
@article{81d308504307410db04e787ab2dbf35a,
title = "Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex",
abstract = "Intravenous iron is necessary for optimal management of anemia in patients receiving hemodialysis and is utilized in the majority of these patients in the US. The availability of nondextran formulations of intravenous iron has significantly improved the safety of its use. The nondextran iron formulation sodium ferric gluconate complex (SFGC) has been extensively studied in the hemodialysis population, with two large phase IV trials documenting its safety. SFGC is efficacious and, at recommended doses, is associated with a low incidence of adverse events. There have been few comparative studies of the nondextran intravenous iron preparations; however, they are known to have different pharmacokinetic characteristics. There is also evidence to indicate that these compounds differ in terms of their cytotoxic and proinflammatory properties, and their propensity to induce oxidative stress. This paper reviews the current literature on the safety of SFGC and examines the emerging safety issues surrounding the use of intravenous iron.",
keywords = "Anemia, End-stage renal disease, Intravenous iron, Iron deficiency, Sodium ferric gluconate complex",
author = "Beckie Michael and Steven Fishbane and Coyne, {Daniel W.} and Rajiv Agarwal and Warnock, {David G.}",
year = "2006",
month = "2",
day = "1",
doi = "10.1038/ncpneph0068",
language = "English (US)",
volume = "2",
pages = "92--100",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Drug insight

T2 - Safety of intravenous iron supplementation with sodium ferric gluconate complex

AU - Michael, Beckie

AU - Fishbane, Steven

AU - Coyne, Daniel W.

AU - Agarwal, Rajiv

AU - Warnock, David G.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Intravenous iron is necessary for optimal management of anemia in patients receiving hemodialysis and is utilized in the majority of these patients in the US. The availability of nondextran formulations of intravenous iron has significantly improved the safety of its use. The nondextran iron formulation sodium ferric gluconate complex (SFGC) has been extensively studied in the hemodialysis population, with two large phase IV trials documenting its safety. SFGC is efficacious and, at recommended doses, is associated with a low incidence of adverse events. There have been few comparative studies of the nondextran intravenous iron preparations; however, they are known to have different pharmacokinetic characteristics. There is also evidence to indicate that these compounds differ in terms of their cytotoxic and proinflammatory properties, and their propensity to induce oxidative stress. This paper reviews the current literature on the safety of SFGC and examines the emerging safety issues surrounding the use of intravenous iron.

AB - Intravenous iron is necessary for optimal management of anemia in patients receiving hemodialysis and is utilized in the majority of these patients in the US. The availability of nondextran formulations of intravenous iron has significantly improved the safety of its use. The nondextran iron formulation sodium ferric gluconate complex (SFGC) has been extensively studied in the hemodialysis population, with two large phase IV trials documenting its safety. SFGC is efficacious and, at recommended doses, is associated with a low incidence of adverse events. There have been few comparative studies of the nondextran intravenous iron preparations; however, they are known to have different pharmacokinetic characteristics. There is also evidence to indicate that these compounds differ in terms of their cytotoxic and proinflammatory properties, and their propensity to induce oxidative stress. This paper reviews the current literature on the safety of SFGC and examines the emerging safety issues surrounding the use of intravenous iron.

KW - Anemia

KW - End-stage renal disease

KW - Intravenous iron

KW - Iron deficiency

KW - Sodium ferric gluconate complex

UR - http://www.scopus.com/inward/record.url?scp=33644829151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644829151&partnerID=8YFLogxK

U2 - 10.1038/ncpneph0068

DO - 10.1038/ncpneph0068

M3 - Review article

C2 - 16932400

AN - SCOPUS:33644829151

VL - 2

SP - 92

EP - 100

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 2

ER -